We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Xceed Grants License for Flow-Thru Chip Technology

By Labmedica staff writers
Posted on 11 Jun 2008
Xceed Molecular (Toronto, Canada) has granted Gen-Probe (Wellesley, MA, USA) a license to use its Flow-Thru Chip technology for multiplex molecular diagnostics.

Under the terms of the agreement, Gen-Probe will pay up-front licensing and milestone fees to Xceed for non-exclusive access to the technology in specific fields. More...
Gen-Probe also obtained the right to obtain co-exclusive rights (with Xceed) in pre-defined subfields. In addition to continuing royalty payments, the agreement provides that Xceed will supply Gen-Probe with Xceed's custom TipChips, its Ziplex automated gene-expression system, and other Xceed products. Additional terms were not disclosed.

Xceed's 3D Flow-Thru Chip design enables active transport of targets to probes. The chip is made of porous silicon with channels that extend from the upper to the lower surface of the chip. Molecular interactions occur within the three-dimensional matrix of these channels as target solutions pass through. This approach facilitates specific interactions between target molecules and immobilized probes, resulting in hybridization times that are three- to four-times faster than conventional methods.

Gen-Probe's executive vice president and chief scientist, Dan Kacian, Ph.D., M.D., commented, "There are many promising applications for moderate-density arrays in clinical diagnostics and other applications, and we believe that Xceed's technologies in combination with our own technologies will facilitate our entry into these expanding markets.”

Xceed Molecular is a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems. Gen-Probe is a global leader in the development, manufacture, and marketing of rapid, accurate, and cost-effective nucleic acid testing products for diagnosing human diseases and screening donated human blood.


Related Links:
Xceed Molecular
Gen-Probe

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.